Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Prostatic acid phosphatase by radioimmunoassay

Journal Article · · J. Am. Med. Assoc.; (United States)
Prostatic acid phosphatase values in 98 patients with prostatic carcinoma were measured by a commmercial radioimmunoassay (RIA) and by enzymatic assay. Forty-three carcinomas were staged by rigorous pathological criteria. Patients (N = 129) with benign prostatic hyperplasia were the control group. At 94% specificity, sensitivities of the RIA vs the enzymatic assay for clinically staged patients were as follows: stage A, 22% vs 6%; B, 29% vs 10%; C, 52% vs 38%; and D, 87% vs 80%. However, none of the seven patients with pathological stage A and B disease had a positive test result, and we suggest that variability in staging criteria accounts for the discrepant sensitivity claims reported. Prostatic acid phosphatase RIA should not be used for screening but as an adjunct for staging known prostatic carcinoma.
Research Organization:
Swedish Hospital Medical Center, Seattle, WA
OSTI ID:
7079804
Journal Information:
J. Am. Med. Assoc.; (United States), Journal Name: J. Am. Med. Assoc.; (United States) Vol. 244:18; ISSN JAMAA
Country of Publication:
United States
Language:
English